{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:02:25Z","timestamp":1792072945406,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03351-5","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T14:02:23Z","timestamp":1685455343000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"85","author":[{"given":"Shaomin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"1","key":"3351_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Z. Younossi et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15(1), 11\u201320 (2018). https:\/\/doi.org\/10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"3351_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"N. Chalasani et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1), 328\u2013357 (2018). https:\/\/doi.org\/10.1002\/hep.29367","journal-title":"Hepatology"},{"issue":"9","key":"3351_CR3","doi-asserted-by":"publisher","first-page":"e2230436","DOI":"10.1001\/jamanetworkopen.2022.30436","volume":"5","author":"JF Huang","year":"2022","unstructured":"J.F. Huang, M.L. Yu, W.L. Chuang, Simulation of long-term outcomes in patients with nonalcoholic fatty liver disease. JAMA Netw Open 5(9), e2230436 (2022). https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.30436","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3351_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Z.M. Younossi et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64(5), 1577\u20131586 (2016). https:\/\/doi.org\/10.1002\/hep.28785","journal-title":"Hepatology"},{"issue":"5","key":"3351_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/17474124.2018.1460202","volume":"12","author":"FB Lu","year":"2018","unstructured":"F.B. Lu et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Exp Rev Gastroenterol Hepatol 12(5), 491\u2013502 (2018). https:\/\/doi.org\/10.1080\/17474124.2018.1460202","journal-title":"Exp Rev Gastroenterol Hepatol"},{"issue":"4","key":"3351_CR6","first-page":"184","volume":"17","author":"NT Gunn","year":"2021","unstructured":"N.T. Gunn, Lean nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Gastroenterol Hepatol 17(4), 184\u2013186 (2021).","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"3351_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/apt.14112","volume":"46","author":"S Sookoian","year":"2017","unstructured":"S. Sookoian, C.J. Pirola, Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther 46(2), 85\u201395 (2017). https:\/\/doi.org\/10.1111\/apt.14112","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3351_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11154-020-09621-1","volume":"22","author":"S Maier","year":"2021","unstructured":"S. Maier et al. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 22(2), 351\u2013366 (2021). https:\/\/doi.org\/10.1007\/s11154-020-09621-1","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"3351_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Q. Ye et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 5(8), 739\u2013752 (2020). https:\/\/doi.org\/10.1016\/s2468-1253(20)30077-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"3351_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2006.06.013","volume":"45","author":"M Machado","year":"2006","unstructured":"M. Machado, Marques-Vidal, H. Cortez-Pinto, Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45(4), 600\u2013606 (2006). https:\/\/doi.org\/10.1016\/j.jhep.2006.06.013","journal-title":"J Hepatol"},{"issue":"1","key":"3351_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1467-789x.2004.00126.x","volume":"5","author":"D Festi","year":"2004","unstructured":"D. Festi et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 5(1), 27\u201342 (2004). https:\/\/doi.org\/10.1111\/j.1467-789x.2004.00126.x","journal-title":"Obes Rev"},{"key":"3351_CR12","first-page":"S542","volume":"75","author":"G Semmler","year":"2021","unstructured":"G. Semmler et al. Prevalence of lean NAFLD vs lean MAFLD indicates a distinct risk of mortality. J Hepatol 75, S542\u2013S544 (2021)","journal-title":"J Hepatol"},{"issue":"6","key":"3351_CR13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cgh.2021.07.016","volume":"20","author":"OT Ahmed","year":"2022","unstructured":"O.T. Ahmed et al. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clin Gastroenterol Hepatol 20(6), 1374\u20131381.e6 (2022). https:\/\/doi.org\/10.1016\/j.cgh.2021.07.016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"3351_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.15403\/jgld-3622","volume":"30","author":"A Feldman","year":"2021","unstructured":"A. Feldman et al. Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects. J Gastrointestin Liver Dis 30(3), 366\u2013373 (2021). https:\/\/doi.org\/10.15403\/jgld-3622","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"3351_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep4.1124","volume":"2","author":"H Hagstrom","year":"2018","unstructured":"H. Hagstrom et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun 2(1), 48\u201357 (2018). https:\/\/doi.org\/10.1002\/hep4.1124","journal-title":"Hepatol Commun"},{"issue":"1","key":"3351_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000478719","volume":"2","author":"E Aigner","year":"2017","unstructured":"E. Aigner et al. 1st International Conference on Fatty Liver (ICFL). Seville, June 1-3, 2017. Abstracts. Inflammatory Intestinal Diseases 2(1), 1\u201392 (2017). https:\/\/doi.org\/10.1159\/000478719","journal-title":"Abstracts. Inflammatory Intestinal Diseases"},{"issue":"1","key":"3351_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.28697","volume":"65","author":"JCF Leung","year":"2017","unstructured":"J.C.F. Leung et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology 65(1), 54\u201364 (2017). https:\/\/doi.org\/10.1002\/hep.28697","journal-title":"Hepatology"},{"key":"3351_CR18","doi-asserted-by":"publisher","unstructured":"R. Younes et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut (2021) https:\/\/doi.org\/10.1136\/gutjnl-2020-322564","DOI":"10.1136\/gutjnl-2020-322564"},{"issue":"9","key":"3351_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/1440-1681.12260","volume":"41","author":"Y Xun","year":"2014","unstructured":"Y. Xun et al. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD. Clin Exp Pharmacol Physiol 41(9), 643\u2013649 (2014). https:\/\/doi.org\/10.1111\/1440-1681.12260","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"3351_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1530\/EJE-19-0143","volume":"181","author":"DH Sinn","year":"2019","unstructured":"D.H. Sinn et al. Lean non-alcoholic fatty liver disease and development of diabetes: A cohort study. Eur J Endocrinol 181(2), 185\u2013192 (2019). https:\/\/doi.org\/10.1530\/EJE-19-0143","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3351_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12072-018-9916-4","volume":"13","author":"MA Niriella","year":"2019","unstructured":"M.A. Niriella et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatol Int 13(3), 314\u2013322 (2019). https:\/\/doi.org\/10.1007\/s12072-018-9916-4","journal-title":"Hepatol Int"},{"issue":"2","key":"3351_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/liv.12912","volume":"36","author":"T Fukuda","year":"2016","unstructured":"T. Fukuda et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 36(2), 275\u2013283 (2016). https:\/\/doi.org\/10.1111\/liv.12912","journal-title":"Liver Int"},{"issue":"8","key":"3351_CR23","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/hep4.1534","volume":"4","author":"P Golabi","year":"2020","unstructured":"P. Golabi et al. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. Hepatol Commun 4(8), 1136\u20131148 (2020). https:\/\/doi.org\/10.1002\/hep4.1534","journal-title":"Hepatol Commun"},{"issue":"7","key":"3351_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.acra.2018.08.019","volume":"26","author":"L Wang","year":"2019","unstructured":"L. Wang, Ultrasound-Diagnosed Nonalcoholic Fatty Liver Disease Independently Predicts a Higher Risk of Developing Diabetes Mellitus in Nonoverweight Individuals. Acad Radiol 26(7), 863\u2013868 (2019). https:\/\/doi.org\/10.1016\/j.acra.2018.08.019","journal-title":"Acad Radiol"},{"issue":"1","key":"3351_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/cd18-0026","volume":"37","author":"P Golabi","year":"2019","unstructured":"P. Golabi et al. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes 37(1), 65\u201372 (2019). https:\/\/doi.org\/10.2337\/cd18-0026","journal-title":"Clin Diabetes"},{"issue":"12","key":"3351_CR26","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.2337\/dc10-0606","volume":"33","author":"JY Yim","year":"2010","unstructured":"J.Y. Yim et al. Sagittal abdominal diameter is a strong anthropometric measure of visceral adipose tissue in the Asian general population. Diabetes Care 33(12), 2665\u20132670 (2010). https:\/\/doi.org\/10.2337\/dc10-0606","journal-title":"Diabetes Care"},{"issue":"4","key":"3351_CR27","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/hep.30908","volume":"71","author":"F Chen","year":"2020","unstructured":"F. Chen et al. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology 71(4), 1213\u20131227 (2020). https:\/\/doi.org\/10.1002\/hep.30908","journal-title":"Hepatology"},{"issue":"8","key":"3351_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","volume":"76","author":"Z Safari","year":"2019","unstructured":"Z. Safari, Gerard, The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 76(8), 1541\u20131558 (2019). https:\/\/doi.org\/10.1007\/s00018-019-03011-w","journal-title":"Cell Mol Life Sci"},{"key":"3351_CR29","doi-asserted-by":"publisher","unstructured":"Y. Yun et al. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects. PLoS ONE. 14(3), (2019). https:\/\/doi.org\/10.1371\/journal.pone.0213692","DOI":"10.1371\/journal.pone.0213692"},{"issue":"2","key":"3351_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41575-018-0100-z","volume":"16","author":"S Kopetz","year":"2019","unstructured":"S. Kopetz, A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. Nat Rev Gastroenterol Hepatol 16(2), 79\u201380 (2019). https:\/\/doi.org\/10.1038\/s41575-018-0100-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3351_CR31","doi-asserted-by":"publisher","unstructured":"H. Lin et al. Association of genetic variations with NAFLD in lean individuals. Liver Int (2021). https:\/\/doi.org\/10.1111\/liv.15078","DOI":"10.1111\/liv.15078"},{"issue":"5","key":"3351_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jceh.2019.02.001","volume":"9","author":"G Bale","year":"2019","unstructured":"G. Bale et al. Whole-Exome Sequencing Identifies a Variant in Phosphatidylethanolamine N-Methyltransferase Gene to be Associated With Lean-Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 9(5), 561\u2013568 (2019). https:\/\/doi.org\/10.1016\/j.jceh.2019.02.001","journal-title":"J Clin Exp Hepatol"},{"key":"3351_CR33","doi-asserted-by":"publisher","unstructured":"B. Amirkalali et al. Relationship between Dietary Macronutrient Composition and Nonalcoholic Fatty Liver Disease in Lean and Non-Lean Populations: A Cross-Sectional Study. Public Health Nutr 1\u201331 (2021). https:\/\/doi.org\/10.1017\/S1368980021001762","DOI":"10.1017\/S1368980021001762"},{"issue":"11","key":"3351_CR34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"A. Mantovani et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6(11), 903\u2013913 (2021). https:\/\/doi.org\/10.1016\/S2468-1253(21)00308-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3351_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.5009\/gnl210084","volume":"16","author":"Y Kim","year":"2022","unstructured":"Y. Kim et al. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. Gut Liver 16(2), 290\u2013299 (2022). https:\/\/doi.org\/10.5009\/gnl210084","journal-title":"Gut Liver"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03351-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T05:28:31Z","timestamp":1720848511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03351-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3351"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03351-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"30 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}